Personal Injury
Green, Schafle & Gibbs
More Generic Zantac Recalls Over Possible ...

Recalls of generic Zantac believed to be contaminated by a carcinogen continue to flood in. Two other firms have declared recalls of ranitidine heartburn meds in 150 mg and 300 mg doses. The news arrived even as the degree of the drug returns increased with Mylan’s impromptu recall of three lots of nizatidine capsules last week because the API in them also held dangerous levels of NDMA.

More Generic Zantac Recalls Over Possible Contamination
Personal Injury
Green, Schafle & Gibbs
Why Companies Recalled Heartburn Medications

Shortly after the Federal officials announced the voluntary recalls of some pharmacies over NDMA, a drug filled with a potential human carcinogen, many other pharmacies have recalled the common variety of heartburn drug Zantac, called ranitidine, from shelves.

Why Companies Recalled Heartburn Medications
Personal Injury
Green, Schafle & Gibbs
Zantac Generics Recall Grows Due to Cancer Risk

Additional generic editions of Zantac are being taken down from pharmacy shelves after officials detected low levels of a possible carcinogens in the heartburn medication.

Zantac Generics Recall Grows Due to Cancer Risk
Personal Injury
Green, Schafle & Gibbs
Stryker Hip Implant Failures

The Stryker Tritanium Acetabular Shell, which restores the human hip socket, is built from a titanium alloy covered with a unique kind of porous foam. The foam enables bone cells to bind with it and grow, thereby increasing joint stability. However, a 2018 report in the journal Arthroplasty Today by doctors at NYU Langone Orthopedic Hospitals described five hip implant failures related to Stryker’s Tritanium cups between 2011 and 2016.

Stryker Hip Implant Failures
Personal Injury
Green, Schafle & Gibbs
Stryker Recalls Femoral Head Implants

Medical technology giant, Stryker Corporation, has issued an urgent voluntary recall of its femoral head implants due to evidence that they may cause serious medical issues.

Stryker Recalls Femoral Head Implants

securities law

New Rule May Have Big Impact on Older Investor Claimants

New Rule May Have Big Impact on Older Investor Claimants

According to a recent announcement from FINRA’s Office of Dispute Resolution, they are drafting a new rule which would tag cases involving claimants 75 years or older for expediting processing. FINRA already has expedited processing available for 65 year or older or sick claimants — but the deadlines that generally determine the timing of the arbitration do not change. FINRA’s new rule would tackle that problem and hopefully greatly improve how quickly expedited claims move through the process by changing — ie, shortening — the actual deadlines.

The Broker Oath - But Will It Work?

The Broker Oath - But Will It Work?

Thanks to a recent decision by the Fifth Circuit, it appears that brokers will, once again, get off the hook when it comes putting their clients' interests in front of their own. Into the breach has stepped an idea that has been kicking around for a years now, but which may be the best of several uninspiring options to compel brokers to act more responsibly toward investors: The Oath.

FINRA Targets Rogue Brokers with History of Abuse

FINRA Targets Rogue Brokers with History of Abuse

The Financial Industry Regulatory Authority (FINRA) has released a serious of proposals aimed at implementing tougher supervisory protocols on brokers with a history of misconduct. Sponsoring brokerages would be forced to institute heightened supervisory measures on these brokers or be held responsible for any subsequent transgressions.

Securities Industry and the "Best Interest Standard" for Investors

Securities Industry and the "Best Interest Standard" for Investors

For decades, broker dealers and financial advisors were only required to uphold their “fiduciary duty” toward client-investors. Now the US Department of Labor and FINRA are working together to enforce a higher standard of care - the "best interest standard." But is it really a higher standard?

FIRM LOCATION:

PHILADELPHIA

2332 South Broad Street

Philadelphia PA 19145

p: 215 462 3330 / f: 215-567-1941